D. Osborne
Directeur Financier/CFO chez Melt Pharmaceuticals, Inc.
Postes actifs de D. Osborne
Sociétés | Poste | Début | Fin |
---|---|---|---|
Melt Pharmaceuticals, Inc.
Melt Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Melt Pharmaceuticals, Inc. engages in the development and commercialization of proprietary non-opioid, non-intravenous, or non-IV, sedation and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings. It intends to seek regulatory approval through the FDA regulatory pathway for the proprietary, patented small-molecule product candidates. The company was founded by Mark L. Baum on April 3, 2018 and is headquartered in Brentwood, TN. | Directeur Financier/CFO | 01/02/2022 | - |
Historique de carrière de D. Osborne
Anciens postes connus de D. Osborne
Sociétés | Poste | Début | Fin |
---|---|---|---|
PRECIGEN, INC. | Comptroller/Controller/Auditor | 01/04/2016 | 10/06/2021 |
Directeur Financier/CFO | - | 10/06/2021 | |
Corporate Officer/Principal | 01/07/2011 | 01/04/2016 |
Statistiques
Internationale
Etats-Unis | 3 |
Opérationnelle
Director of Finance/CFO | 2 |
Comptroller/Controller/Auditor | 1 |
Corporate Officer/Principal | 1 |
Sectorielle
Health Technology | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
PRECIGEN, INC. | Health Technology |
Entreprise privées | 1 |
---|---|
Melt Pharmaceuticals, Inc.
Melt Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Melt Pharmaceuticals, Inc. engages in the development and commercialization of proprietary non-opioid, non-intravenous, or non-IV, sedation and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings. It intends to seek regulatory approval through the FDA regulatory pathway for the proprietary, patented small-molecule product candidates. The company was founded by Mark L. Baum on April 3, 2018 and is headquartered in Brentwood, TN. | Health Technology |
- Bourse
- Insiders
- D. Osborne
- Expérience